← Back to headlines
Cavendish Maintains Buy Rating on Shield Therapeutics Following Viatris Partnership Deal
The investment bank reaffirmed its positive outlook on the biotech firm after it secured a strategic commercial agreement with pharmaceutical giant Viatris in the United States.
28 Aug, 09:15 — 28 Aug, 09:15
Sources
Showing 1 of 1 sources
